Literature DB >> 6494443

The genotoxicity of alpha particles in human embryonic skin fibroblasts.

D J Chen, G F Strniste, N Tokita.   

Abstract

Cell inactivation and induced mutation frequencies at the hypoxanthine-guanine phosphoribosyl transferase (HGPRT) locus have been measured in cultured human fibroblasts (GM10) exposed to alpha particles from 238Pu (LET at the cell surface was 100 keV/microns) and 250 kVp X rays. The survival curves resulting from exposure to alpha particles are exponential. The mean lethal dose, D0, is approximately 1.3 Gy for X rays and 0.25 Gy for alpha particles. As a function of radiation dose, mutation induction at the HGPRT locus was linear for alpha particles whereas the X-ray-induced mutation data were better fitted by a quadratic function. When mutation frequencies were plotted against the log of survival, mutation frequency at a given survival level was greater in cells exposed to alpha particles than to X rays.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6494443

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  4 in total

1.  Ultraviolet-induced movement of the human DNA repair protein, Xeroderma pigmentosum type G, in the nucleus.

Authors:  M S Park; J A Knauf; S H Pendergrass; C H Coulon; G F Strniste; B L Marrone; M A MacInnes
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

Review 2.  From energy deposition to cancer.

Authors:  W Burkart
Journal:  Soz Praventivmed       Date:  1991

Review 3.  The cellular and molecular carcinogenic effects of radon exposure: a review.

Authors:  Aaron Robertson; James Allen; Robin Laney; Alison Curnow
Journal:  Int J Mol Sci       Date:  2013-07-05       Impact factor: 5.923

Review 4.  Radon and Lung Cancer: Current Trends and Future Perspectives.

Authors:  Mariona Riudavets; Marta Garcia de Herreros; Benjamin Besse; Laura Mezquita
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.